How TrivarX’s Stabl-Im Could Revolutionize Early Brain Tumour Detection
TrivarX Limited has exercised its option to acquire the innovative Stabl-Im brain imaging technology, aiming to revolutionize early detection of brain tumours pending shareholder approval.
- Option exercised to acquire Stabl-Im metastatic brain imaging technology
- Technology enables early, non-invasive detection of brain tumours via stable isotope MRI
- Acquisition subject to shareholder approval expected mid-December 2025
- Plans include manufacturing validation, regulatory engagement, and Phase 1 trial in 2026
- Targets significant unmet need in brain metastases diagnostics
TrivarX Moves Into Oncology Diagnostics
TrivarX Limited, an ASX-listed mental health technology company, has taken a decisive step to broaden its diagnostic portfolio by exercising its option to acquire the Stabl-Im metastatic brain imaging technology from Nucleics Pty Ltd. This move, announced on 5 November 2025, marks a strategic expansion into oncology, specifically targeting the early detection and monitoring of brain tumours.
A Potential Paradigm Shift in Brain Cancer Imaging
Stabl-Im represents a novel approach to brain tumour imaging by using stable isotope labelling detectable through MRI scans. Unlike conventional MRI methods that typically identify tumours only once they reach a size of 2 to 3 millimeters, Stabl-Im aims to detect proliferating tumour cells at much earlier stages. This non-invasive and radiation-free technology could significantly improve clinical decision-making by providing a safe, repeatable method to monitor tumour activity.
Addressing a Critical Unmet Medical Need
Brain metastases affect up to 20% of adult cancer patients and are associated with limited treatment options and poor prognosis. Early detection is crucial but remains challenging with current imaging techniques. By enabling earlier visualization of tumour growth, Stabl-Im has the potential to transform patient outcomes and fill a major gap in brain cancer diagnostics.
Next Steps and Regulatory Pathway
The acquisition is contingent on shareholder approval at a general meeting expected in mid-December 2025. Upon approval, TrivarX plans to initiate a comprehensive development program, including manufacturing and quality-control validation of the imaging compounds, regulatory engagement with both the US Food and Drug Administration and European Union authorities, and the design and commencement of a Phase 1 clinical trial scheduled for calendar year 2026.
Leadership Perspective and Strategic Outlook
Non-executive Chairman David Trimboli highlighted the significance of this acquisition, emphasizing its alignment with TrivarX’s mission to develop safe, non-invasive diagnostic technologies. He described Stabl-Im as a potential game-changer in brain cancer imaging that complements the company’s existing neurodiagnostic programs and positions TrivarX at the forefront of precision imaging innovation.
Bottom Line?
TrivarX’s acquisition of Stabl-Im could redefine brain tumour diagnostics, but success hinges on regulatory approvals and clinical validation.
Questions in the middle?
- Will shareholder approval be secured without delay in December 2025?
- How will regulatory agencies respond to this novel imaging technology?
- What clinical outcomes will the Phase 1 trial reveal about safety and efficacy?
